Rare diseases and orphan drugs in Japan: Developing multiple strategies of regulation and research

Expert Opinion on Orphan Drugs

Volumn 1, Issue 9, 2013, Pages 681-683

  Song, Peipei ^a   Tang, Wei ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Database; Drug discovery; Health system; Orphan drug legislation

Indexed keywords

ORPHAN DRUG;

CLINICAL RESEARCH; HUMAN; JAPAN; LAW; MARKETING; PROSPECTIVE PRICING; RARE DISEASE; REGULATORY MECHANISM; REIMBURSEMENT; REVIEW;

EID: 84896733265     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.832201     Document Type: Review

References (12)

1. Japan Intractable Diseases Information Center. What is an intractable disease? Available from: http://www.nanbyou.or. jp [Last accessed 16 June 2013]
2. Song PP, Kokudo N. Revision of measures to combat intractable diseases in Japan: three pillars will play an even greater role in the future. Intractable Rare Dis Res 2013;2:33-4
3. Song PP, Gao JJ, Inagaki Y, et al. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res 2012;1:3-9
4. Makoto S, Kiyohito N. Development of orphan drugs in Japan: effects of a support system for development of orphan drugs in Japan. Drug Inf J 2000;34:829-37
5. Makoto S, Kiyohito N. Development of orphan drugs in Japan: characteristics of orphan drugs developed in Japan. Drug Inf J 2000;34:839-46
6. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today 2013;18:163-72
7. Lexchin J. Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. CMAJ 2006;174:1120-1
8. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy 2010;97:173-9
9. Song P, Gao J, Inagaki Y, et al. Intractable and rare diseases research i The Japanese Ministry of Health, Labour, and Welfare. Reform of measures to combat intractable diseases. Available from: http://www.mhlw.go.jp/ stf/shingi/2r9852000002n6ro-att/ 2r9852000002n6uj.pdf [Last accessed 25 June 2013]; in Japanese
10. Song PP, Gao JJ, Kokudo N, Tang W. New opportunity for orphan drug development in Japan: early exploratory clinical trial bases promote drug translation from basic studies to clinical application. Intractable Rare Dis Res 2012;1:95-7
11. Inagaki Y, Song PP. Necessity of cooperation with government on publication of scientific research results for intractable diseases. Intractable Rare Dis Res 2013;2:69-71
12. EURORDIS. Survey of the delay in diagnosis for 8 rare diseases in Europe (Eurordiscare 2). Available from: http://archiveeurordis.org/article.php3?id- article=454 [Last accessed 1 July 2013]